Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,972,790
  • Shares Outstanding, K 68,261
  • Annual Sales, $ 90,730 K
  • Annual Income, $ -115,980 K
  • 60-Month Beta 1.95
  • Price/Sales 47.55
  • Price/Cash Flow N/A
  • Price/Book 7.60
Trade EDIT with:

Options Overview

Details
  • Implied Volatility 127.59%
  • Historical Volatility 72.04%
  • IV Percentile 91%
  • IV Rank 70.80%
  • IV High 154.71% on 02/01/21
  • IV Low 61.80% on 06/21/21
  • Put/Call Vol Ratio 0.98
  • Today's Volume 15,363
  • Volume Avg (30-Day) 5,974
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 49,540
  • Open Int (30-Day) 52,801

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.86
  • Number of Estimates 6
  • High Estimate -0.78
  • Low Estimate -0.96
  • Prior Year 0.12
  • Growth Rate Est. (year over year) -816.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.25 +1.66%
on 09/20/21
73.03 -20.30%
on 09/02/21
-2.18 (-3.61%)
since 08/20/21
3-Month
34.75 +67.48%
on 06/21/21
73.03 -20.30%
on 09/02/21
+22.32 (+62.21%)
since 06/18/21
52-Week
27.01 +115.48%
on 10/02/20
99.95 -41.77%
on 01/08/21
+24.30 (+71.68%)
since 09/18/20

Most Recent Stories

More News
Aadi Bioscience Appoints Emma Reeve to its Board of Directors

Aadi Bioscience, Inc. ("Aadi") (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced...

AADI : 29.09 (-0.89%)
PTCT : 41.59 (-2.44%)
EDIT : 58.20 (-7.91%)
Editas Medicine Names Emma Reeve to Board of Directors

Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Emma Reeve to its Board of Directors.

EDIT : 58.20 (-7.91%)
Initial Clinical Data from Editas Medicine's BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September

Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity

EDIT : 58.20 (-7.91%)
Why You Need to Avoid These 3 Downgraded Stocks

Our proprietary POWR Ratings system evaluates stocks based on 118 different factors. Investors should only consider buying stocks rated a Strong Buy or Buy, and should definitely avoid stocks rated a Sell...

EDIT : 58.20 (-7.91%)
VISL : 1.7400 (-9.37%)
ESYJY : 11.4877 (+2.16%)
Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EDIT : 58.20 (-7.91%)
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe

Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The drug has seen solid uptake since its launch. However, sole dependence on Oxbryta for growth remains a concern.

NVS : 82.80 (-0.81%)
RHHBY : 45.5700 (-1.09%)
GBT : 27.10 (-3.32%)
EDIT : 58.20 (-7.91%)
NASDAQ Jumps Over 2.5% in 2 Days to Close at Record High

NASDAQ Jumps Over 2.5% in 2 Days to Close at Record High

AI : 47.06 (-6.11%)
DKS : 131.91 (-1.07%)
CAR : 94.93 (-0.41%)
TXT : 68.60 (+0.20%)
CBRE : 94.53 (-1.31%)
CB : 177.89 (-1.47%)
IPG : 36.22 (-2.08%)
SKX : 44.83 (-0.86%)
TPX : 47.63 (+0.11%)
VRT : 23.86 (+0.55%)
DVAX : 14.97 (+0.54%)
EDIT : 58.20 (-7.91%)
PFE : 44.20 (+0.71%)
BBY : 106.67 (-2.69%)
JWN : 27.78 (-1.21%)
URBN : 32.15 (-1.14%)
AAP : 203.71 (-1.02%)
TOL : 60.69 (-3.50%)
Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory's Genome Engineering: CRISPR Frontiers Meeting

SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells

EDIT : 58.20 (-7.91%)
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.

BEAM : 95.31 (-7.39%)
EDIT : 58.20 (-7.91%)
NTLA : 148.36 (-5.68%)
CRSP : 116.47 (-6.46%)
How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

BEAM : 95.31 (-7.39%)
EDIT : 58.20 (-7.91%)
PBE : 76.17 (-1.98%)
NTLA : 148.36 (-5.68%)
CRSP : 116.47 (-6.46%)
ARKG : 80.33 (-4.29%)
GNOM : 23.25 (-4.00%)
IDNA : 53.54 (-3.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 65.57
2nd Resistance Point 63.71
1st Resistance Point 60.96
Last Price 58.20
1st Support Level 56.35
2nd Support Level 54.49
3rd Support Level 51.74

See More

52-Week High 99.95
Fibonacci 61.8% 72.09
Fibonacci 50% 63.48
Last Price 58.20
Fibonacci 38.2% 54.87
52-Week Low 27.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar